Sunteți pe pagina 1din 3

SILVA, JOSEPH PAULO L.

03/05/2017
BIO 101 C-2

Improving quality of produce and


Curing Diseases

Watson and Crick 1953


Watson 1958

Central Dogma of Molecular Biology

What is Antisense technology?


Antisense Technology: Antisense
oligonucleotides and RNA
Interference
Silva, Joseph Paulo L.
C-2
BIO101

General Outline of Antisense


Technology

Antisense technology 1
SILVA, JOSEPH PAULO L. 03/05/2017
BIO 101 C-2

Antisense Oligonucleotides RNA Interference


Synthetic
Complementary to target
RNA
RNase H or steric
blocking
Modifications in the
sugar, nucleobase, and
phosphate backbone
improve stability in vivo
and make the ODNs
more lipid soluble

Applications of AST
FLAVR SAVR - RNAi
Procedures and Sample Results Cassava Mosaic Model - RNAi
on applications of AST Fomivirsen Antisense Oligonucleotides

FLAVR SAVR African Cassava Mosaic Disease

Antisense technology 2
SILVA, JOSEPH PAULO L. 03/05/2017
BIO 101 C-2

Formivirsen
References
CHERY, J. (2016) RNA therapeutics: RNAi and antisense mechanisms and clinical
Phosphorothioate (Phosphate backbone mod.) ODNs. applications. Harvard Medical School, Department of Cell Biology, Massachusetts
General Hospital Cancer Center Boston, MA 02129
Dose delivered with needle injection. COLMAN, A. (1990) Antisense strategies in cell and developmental biology. Journal
of cell science. 97 ( Pt 3). 399-409. 0021-9533 (Print)\n0021-9533 (Linking)
The mean 50% inhibitory concentration between 0.03
DE SMET, M. D., MEENKEN, C. J., & VAN DEN HORN, G. J. (1999). Fomivirsen - a
um for retinal pigment epithelial cells and 0.2 um for phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocular
human fibroblast Immunology and Inflammation, 7(34), 18998.
http://doi.org/10.1076/ocii.7.3.189.4007
Formivirsen inhibited CMV replication in human retinal GUPTA, S., SINGH, R. P., RABADIA, N., PATEL, G., & PANCHAL, H. (2011).
Antisense technology. International Journal of Pharmaceutical Sciences Review and
pigment epithelial cells and human fibroblast cells in a Research, 9(2), 3845. https://doi.org/10.2174/138920107782109985
dose dependent manner. KIMBALL, J., Antisense RNA. (2002). http://users.rcn.com/jkimball.ma.ultranet/
BiologyPages/A/AntisenseRNA.html accessed on 03/04/2017
KRIEGER, E. K., ALLEN, E., GILBERTSON, L. A., ROBERTS, J. K., HIATT, W., &
SANDERS, R. A. (2008). The Flavr Savr tomato, an early example of RNAi
technology. HortScience, 43(3), 962964.
MISRA. A. et.al (2011) A Challenges in Delivery of Therapeutic Genomics and
Proteomics. Elsevier accessed on 03/30.2017

RE. R. (2000) The Application of Antisense Technology to Medicine. Ochsner Clinic and
Alton Ochsner Medical Foundation. Elsevier accessed on 03/30.2017
PATERSON, B. M., ROBERTS, B. E. AND KUFF, E (1977). Structural gene identification and
mapping by DNA-mRNA hybrid-arrest cell free translation. Proc. natn. Acad. Sci. U.S.A. 74,
4370-4374.
WALTON, S. P., ROTH, C. M., YARMUSH, M. L. (2010) Antisense Technology.The
Biomedical Engineering Handbook: Second Edition.
WATTS J.K, COREY D.R (2012). Gene silencing by siRNAs and antisense oligonucleotides
in the laboratory and the clinic. Departments of Pharmacology and Biochemistry, University
of Texas Southwestern Medical Center, Dallas, USA, TX 75390-9041
WICKSTROM, E., BACON, T, GONZALEZ, A., FREEMAN, D., and LYMAN, G. (1988).
Human promyelocytic leukemia HL-60 cell proliferation and c-myc expression are inhibited
by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc. natn. Acad.
Sci. U.S.A. 85, 1028-1032.
ZAMECNIK, P. C. AND STEPHENSON, M. L. (1978). Inhibition of Rous sarcoma virus
replication and cell transformation by a specific oligodeoxynucleotide. Proc. natn. Acad. Sci.
U.S.A. 75, 280-284
ZHANG, P., VANDERSCHUREN, H., FTTERER, J., & GRUISSEM, W. (2005). Resistance
to cassava mosaic disease in transgenic cassava expressing antisense RNAs targeting virus
replication genes. Plant Biotechnology Journal, 3(4), 385397. http://doi.org/10.1111/j.1467-
7652.2005.00132.x

Antisense technology 3

S-ar putea să vă placă și